World Journal of *Clinical Cases*

World J Clin Cases 2023 April 16; 11(11): 2363-2581





Published by Baishideng Publishing Group Inc

W J C C World Journal of Clinical Cases

Contents

Thrice Monthly Volume 11 Number 11 April 16, 2023

REVIEW

2363 Presbyphagia: Dysphagia in the elderly

Feng HY, Zhang PP, Wang XW

MINIREVIEWS

2374 Narrative minireview of the spatial epidemiology of substance use disorder in the United States: Who is at risk and where?

Cuadros DF, Branscum AJ, Moreno CM, MacKinnon NJ

- 2386 Pyroptosis and its role in cancer Liu SW, Song WJ, Ma GK, Wang H, Yang L
- 2396 Platelet rich fibrin is not a barrier membrane! Or is it? Agrawal AA
- 2405 Advances in translational therapy for locally advanced gastric cancer Zhao K, Na Y, Xu HM

ORIGINAL ARTICLE

Retrospective Study

- 2412 Study of pathogenic genes in a pedigree with familial dilated cardiomyopathy Zhang XR, Ren H, Yao F, Liu Y, Song CL
- 2423 Classification of hepatobiliary scintigraphy patterns in segmented gallbladder according to anatomical discordance

Lee YC, Jung WS, Lee CH, Kim SH, Lee SO

Optimal laboratory testing protocol for patients with acne taking oral isotretinoin 2435 Park YJ, Shin HY, Choi WK, Lee AY, Lee SH, Hong JS

Observational Study

Etiology analysis for term newborns with severe hyperbilirubinemia in eastern Guangdong of China 2443 Xu JX, Lin F, Wu YH, Chen ZK, Ma YB, Yang LY

CASE REPORT

Aicardi-Goutières syndrome type 7 in a Chinese child: A case report 2452 Lin SZ, Yang JJ, Xie TL, Li JY, Ma JQ, Wu S, Wang N, Wang YJ



Conton	World Journal of Clinical Cases Contents Thrice Monthly Volume 11 Number 11 April 16, 2023	
Conten		
2457	Allergic bronchopulmonary aspergillosis with marked peripheral blood eosinophilia and pulmonary eosinophilia: A case report	
	Zhang XX, Zhou R, Liu C, Yang J, Pan ZH, Wu CC, Li QY	
2464	Late presentation of dural tears: Two case reports and review of literature	
	Xu C, Dong RP, Cheng XL, Zhao JW	
2474	Difficult-to-treat rheumatoid arthritis treated with Abatacept combined with Baricitinib: A case report	
	Qi JP, Jiang H, Wu T, Zhang Y, Huang W, Li YX, Wang J, Zhang J, Ying ZH	
2482	Anesthesia management in a pediatric patient with complicatedly difficult airway: A case report	
	Chen JX, Shi XL, Liang CS, Ma XG, Xu L	
2489	Intracranial large artery embolism due to carotid thrombosis caused by a neck massager: A case report	
	Pan J, Wang JW, Cai XF, Lu KF, Wang ZZ, Guo SY	
2496	Intraductal papillary mucinous neoplasm originating from a jejunal heterotopic pancreas: A case report	
	Huang JH, Guo W, Liu Z	
2502	Application of endoscopic retrograde cholangiopancreatography for treatment of obstructive jaundice after hepatoblastoma surgery: A case report	
	Shu J, Yang H, Yang J, Bian HQ, Wang X	
2510	Total removal of a large esophageal schwannoma by submucosal tunneling endoscopic resection: A case report and review of literature	
	Mu YZ, Zhang Q, Zhao J, Liu Y, Kong LW, Ding ZX	
2521	SMARCA4-deficient undifferentiated thoracic tumor: A case report	
	Kwon HJ, Jang MH	
2528	Prostate-specific antigen reduction after capecitabine plus oxaliplatin chemotherapy: A case report	
	Zou Q, Shen RL, Guo X, Tang CY	
2535	Bilateral carpal tunnel syndrome and motor dysfunction caused by gout and type 2 diabetes: A case report	
	Zhang GF, Rong CM, Li W, Wei BL, Han MT, Han QL	
2541	Pregnancy complicated by juxtaglomerular cell tumor of the kidney: A case report	
	Fu X, Deng G, Wang K, Shao C, Xie LP	
2549	Successful treatment of lichen amyloidosis coexisting with atopic dermatitis by dupilumab: Four case reports	
	Zhu Q, Gao BQ, Zhang JF, Shi LP, Zhang GQ	
2559	Successful treatment of breast metastasis from primary transverse colon cancer: A case report	
	Jiao X, Xing FZ, Zhai MM, Sun P	



Contor	World Journal of Clinical Cases	
Conter	Thrice Monthly Volume 11 Number 11 April 16, 2023	
2567	Different endodontic treatments induced root development of two nonvital immature teeth in the same patient: A case report	
	Chai R, Yang X, Zhang AS	
2576	Autoimmune encephalitis after surgery for appendiceal cancer: A case report	
2070	Mao YH, Li L, Wen LM, Qin JM, Yang YL, Wang L, Wang FR, Zhao YZ	

Contents

Thrice Monthly Volume 11 Number 11 April 16, 2023

ABOUT COVER

Editorial Board Member of World Journal of Clinical Cases, Farooq Shahzad, FACS, MBBS, MS, Assistant Professor, Plastic Surgery Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, United States. fooqs@hotmail.com

AIMS AND SCOPE

The primary aim of World Journal of Clinical Cases (WJCC, World J Clin Cases) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC's CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Hua-Ge Yu; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL World Journal of Clinical Cases	INSTRUCTIONS TO AUTHORS https://www.wignet.com/bpg/gerinfo/204
ISSN ISSN 2307-8960 (online)	GUIDELINES FOR ETHICS DOCUMENTS https://www.wignet.com/bpg/GerInfo/287
LAUNCH DATE April 16, 2013	GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH https://www.wignet.com/bpg/gerinfo/240
FREQUENCY Thrice Monthly	PUBLICATION ETHICS https://www.wjgnet.com/bpg/GerInfo/288
EDITORS-IN-CHIEF	PUBLICATION MISCONDUCT
Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku	https://www.wjgnet.com/bpg/gerinfo/208
EDITORIAL BOARD MEMBERS	ARTICLE PROCESSING CHARGE
https://www.wjgnet.com/2307-8960/editorialboard.htm	https://www.wjgnet.com/bpg/gerinfo/242
PUBLICATION DATE	STEPS FOR SUBMITTING MANUSCRIPTS
April 16, 2023	https://www.wjgnet.com/bpg/GerInfo/239
COPYRIGHT © 2023 Baishideng Publishing Group Inc	ONLINE SUBMISSION https://www.f6publishing.com

© 2023 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com



World Journal of Clinical Cases

Submit a Manuscript: https://www.f6publishing.com

World J Clin Cases 2023 April 16; 11(11): 2521-2527

DOI: 10.12998/wjcc.v11.i11.2521

ISSN 2307-8960 (online)

CASE REPORT

SMARCA4-deficient undifferentiated thoracic tumor: A case report

Hee Jung Kwon, Min Hye Jang

Specialty type: Pathology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0 Grade B (Very good): B, B Grade C (Good): 0 Grade D (Fair): D Grade E (Poor): 0

P-Reviewer: Moshref L, Saudi Arabia; Vyshka G, Albania; Yang L, China

Received: December 20, 2022 Peer-review started: December 20. 2022

First decision: February 17, 2023 Revised: February 27, 2023 Accepted: March 22, 2023 Article in press: March 22, 2023 Published online: April 16, 2023



Hee Jung Kwon, Min Hye Jang, Department of Pathology, Yeungnam University Medical Center, Daegu 42415, South Korea

Corresponding author: Min Hye Jang, MD, PhD, Assistant Professor, Department of Pathology, Yeungnam University Medical Center, 170, Hyeonchung-ro, Nam-gu, Daegu 42415, South Korea. clodious@ynu.ac.kr

Abstract

BACKGROUND

SMARCA4-deficient undifferentiated tumors (SMARCA4-DUTs) present with diverse clinical manifestations and progress to metastasis and even cause death within a few months. This novel subset of undifferentiated tumors occurs in the middle-aged population and is strongly associated with a smoking history. Distinguishing it from other malignancies is challenging.

CASE SUMMARY

A 62-year-old man presented with chest pain for 7 d. The patient had no respiratory symptoms and normal pulmonary function test results. The patient had been a smoker for 8 years and quit smoking 2 years ago. Chest computed tomography revealed a huge mass involving the left upper and lower lung lobes with pericardial invasion and multiple metastases. Tumor samples were obtained using open frozen biopsy, after several unsuccessful attempts. The tumor was composed of sheets of undifferentiated disclosive cells with vesicular nuclei and prominent nucleoli. The differential diagnosis included high-grade lymphoma, germ cell tumor, NUT carcinoma, undifferentiated carcinoma, and sarcoma. The tumor cells were large, arranged in sheets, and did not exhibit glandular or squamous differentiation. Frequent foci of necrosis were noted. There was no evidence of epithelial differentiation on immunohistochemical staining. The SMARCA4 stain showed complete loss of expression of SMARCA4, which is diagnostic.

CONCLUSION

In the present case, thoracic SMARCA4-DUT was diagnosed based on clinical features, absence of epithelial differentiation, and negative SMARCA4 expression.

Key Words: SMARCA4; BRG1; Deficient; Undifferentiated tumor; Thoracic; Case report

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: SMARCA4-deficient undifferentiated tumors are highly aggressive neoplasms. Here, we report a case of a SMARCA4-deficient undifferentiated tumor with characteristic clinical and histological features. The findings of this case could serve as a resource for future studies.

Citation: Kwon HJ, Jang MH. SMARCA4-deficient undifferentiated thoracic tumor: A case report. World J Clin Cases 2023; 11(11): 2521-2527 URL: https://www.wjgnet.com/2307-8960/full/v11/i11/2521.htm

DOI: https://dx.doi.org/10.12998/wjcc.v11.i11.2521

INTRODUCTION

SMARCA4-deficient undifferentiated tumors (SMARCA4-DUTs) are aggressive neoplasms that characteristically involve the thorax. They present with undifferentiated or rhabdoid morphological features with deficiency of Brahma-related gene 1 (BRG1) encoded by SMARCA4. The newly discovered tumor has recently been included in the World Health Organization Classification of Tumors: Thoracic Tumors. The most frequent sites where this tumor occurs are the mediastinum, pulmonary hilum, lung, pleura, and chest wall[1,2]. Most patients present with lung involvement, including variable metastases, at the time of initial diagnosis. Associated symptoms include dyspnea, pain, weight loss, and symptoms based on the involved organs. This tumor is often diagnosed in middle-aged heavy smokers and leads to death within a few months. Over half of the cases are associated with smoking-related emphysema^{[2,} 3]. Most cases occur in the fourth to fifth decades of life with a male predominance. Here, we report a case of thoracic SMARCA4-DUT in an older man with a characteristic clinical presentation.

CASE PRESENTATION

Chief complaints

A 62-year-old man presented with pain in the left chest and right flank for 7 d.

History of present illness

The patient had no respiratory symptoms, and pulmonary function test results were normal.

History of past illness

The patient was previously healthy and had no relevant medical history.

Personal and family history

The patient had been a smoker for 8 years (35 pack-years) and quit smoking 2 years earlier.

Physical examination

Physical examination was unremarkable.

Laboratory examinations

A routine blood examination, including tests for white blood cell count, hemoglobin, and other electrolytes, indicated that all levels were within normal range. However, the results of the biochemical tests indicated a slight increase in lactate dehydrogenase (1824 IU/L, with a reference range of 208-450 IU/L) and C-reactive protein (0.885 mg/dL, with a reference range of 0.0-0.5 mg/dL). A polymerase chain reaction test for coronavirus disease 2019 (COVID-19) was conducted, but no evidence of the virus that causes COVID-19 was found.

Imaging examinations

The posteroanterior view of the chest radiograph showed a lesion of dense consolidation in the left lower pericardial area and calcific nodules consistent with an old tuberculosis scar in both upper lobes (Figure 1A). Additional chest computed tomography revealed several enlarged mediastinal lymph nodes (Figure 1B) and a huge mass with necrosis, involving the upper and lower lobes of the left lung, with invasion of the pericardium (Figure 1C). In addition, a low-attenuation lesion was present in the liver, consistent with a metastatic tumor (Figure 1D). Further, multiple lymphadenopathies were found in the bilateral paratracheal, subcarinal, left hilar, left cardiophrenic, internal mammary, and upper abdominal areas. The right lower lung lobe showed small nodules and mild pericardial effusion, also consistent with metastasis. An approximately 9-cm sized lesion in the left lung showed uneven 18F-



WJCC | https://www.wjgnet.com



DOI: 10.12998/wjcc.v11.i11.2521 Copyright ©The Author(s) 2023.

Figure 1 Imaging results. A: The posteroanterior view of the chest radiograph shows a lesion of dense consolidation in the left lower pericardial area and calcific nodules consistent with an old tuberculosis scar in both upper lobes. Computed tomography reveals a huge mass with necrosis involving the upper and lower lobes of the left lung with invasion of the pericardium; B: Several enlarged mediastinal lymph nodes are exhibited; C: Left lung lesion with pericardial invasion is identified; D: Right liver lobe shows a metastatic tumor; E: An approximately 9-cm sized left lung lesion shows uneven 18F-fluorodeoxyglucose uptake on the positron emission tomography (PET) scan. Further, the PET scan shows numerous metastatic lesions involving the mediastinum (left paratracheal, left cardiophrenic, and celiac lymph nodes); liver; bilateral lung lobes; bones of the skull, bilateral humeri, scapula, left clavicle, sternum, vertebras (cervical, thoracic, lumbar), bilateral ribs, pelvis, and bilateral femurs; peritoneum; and retroperitoneum.

> fluorodeoxyglucose uptake on positron emission tomography (PET; Figure 1E). Further, PET showed numerous metastatic lesions involving the mediastinum; liver; bilateral lung lobes; bones of the skull, bilateral humeri, scapula, left clavicle, sternum, vertebras (cervical, thoracic, lumbar), bilateral ribs, pelvis, and bilateral femurs; peritoneum; and retroperitoneum.

FURTHER DIAGNOSTIC WORKUP

Despite the large size of the tumor, both endobronchial ultrasound-guided transbronchial lung biopsy and bronchial washing performed twice failed to obtain a sufficient amount of tumor cells. Due to necrosis, tumor cells were insufficient for a definitive diagnosis. Tumor specimens were finally obtained from the mediastinal node using mediastinoscopy and pleural biopsy. The largest biopsy sample, measuring $2.5 \text{ cm} \times 1.8 \text{ cm} \times 0.5 \text{ cm}$ in size, was received from the operation theater in the fresh state. The mass had a tan to yellowish cut surface. The representative tissue was fixed in 10% neutral formalin and processed for pathologic examination after a frozen section diagnosis. On hematoxylin and eosin staining, the tumor cells were large, round to epithelioid, arranged in diffuse sheets, and did not exhibit glandular or squamous differentiation (Figure 2). Frequent foci of necrosis were noted on frozen and post fixation tissue sections (Figure 2A and B). The tumor cells showed moderate pleomorphism and had abundant eosinophilic cytoplasm (Figure 2C and D). Nuclei were monotonous and vesicular with conspicuous nucleoli. The mitotic activity was high (Figure 2D). Immunohistochemically, the tumor cells were positive for spalt-like transcription factor 4 (SALL4; Figure 2E), CD34 (Figure 2F), and cytoplasmic p53 (aberrant expression) and negative for CAM5.2, erythroblast transformation-specificrelated gene, AE1/AE3 cytokeratin (Figure 2G), thyroid transcription factor-1, p40, CK5/6, nuclear protein in testis (NUT), CD20, and S100 protein. The SMARCA4 stain showed complete loss of



Baishidena® WJCC | https://www.wjgnet.com



DOI: 10.12998/wjcc.v11.i11.2521 Copyright ©The Author(s) 2023.

Figure 2 Histological features and immunostaining results of the tumor. A and B: The frozen section shows a diffuse sheet of large round to epithelioid tumor cells on frozen section (A, \times 100) and post fixation tissue section (B, \times 100). Frequent necrotic foci are seen (B); C: The tumor cells show no glandular or squamous differentiation and exhibit moderate pleomorphism (\times 200); D: The nuclei are monotonous and vesicular with conspicuous nucleoli. The tumor has eosinophilic cytoplasm and a markedly increased mitotic activity (\times 400); E and F: Immunohistochemical staining for Spalt-like transcription factor 4 (SALL4) (E, \times 100) and CD34 (F, \times 100) exhibits positive results; G: The ancillary test, such as that for AE1/AE3 cytokeratin confirms the absence of epithelial differentiation (\times 100); H: SMARCA4 staining exhibits diagnostic complete loss of expression (\times 100; H: Anaplastic lymphoma kinase (ALK) (D5F3) shows negative activity (\times 100); J and K: Programmed death-ligand 1 (PDL1) tests exhibit positivity (J, SP263, \times 100; K, SP142, \times 100). Staining method: Hematoxylin and eosin staining (A-D); polymer method (E-K).

expression, which was diagnostic. (Figure 2H). Anaplastic lymphoma kinase (ALK, D5F3) showed negative activity (Figure 2I). Programmed death-ligand 1 (PDL1) tests showed positivity (Figure 2J, Ventana SP263; Figure 2K, SP142). No epidermal growth factor receptor mutation was detected on pyrosequencing.

FINAL DIAGNOSIS

Histopathology confirmed the diagnosis of SMARCA4-DUT.

Baishidena® WJCC | https://www.wjgnet.com

April 16, 2023 Volume 11 Issue 11

TREATMENT

After mediastinoscopy and pleural biopsy, the patient was discharged on postoperative day 13 with pain control.

OUTCOME AND FOLLOW-UP

Twenty days after the biopsy, the patient complained of dyspnea on exercise, hoarseness, and a poor general condition. He has not visited the hospital for over 10 mo, thereafter.

DISCUSSION

Thoracic *SMARCA4*-DUT is a newly discovered aggressive malignancy whose pathogenesis remains unclear. The most frequent sites of occurrence of this tumor are the mediastinum, pulmonary hilum, lungs, and pleura or chest wall. *SMARCA4*-DUTs have undifferentiated or rhabdoid morphological features with deficiency of *SMARCA4*. They occur most commonly in young men with a history of heavy smoking, but can occur in patients of any age. In addition to our patient, there have been other reports of the tumor presenting at an advanced age. Associated symptoms include dyspnea, pain, weight loss, and symptoms based on the involved organs. Common sites of metastasis include the lymph nodes, bones, and adrenal glands and rarely the brain[4,5].

The tumor-suppressor role of *SMARCA4* (or *BRG1*) was reported in 2000[6]. Nonsense and frameshift mutations in *SMARCA4* are the dominant oncogenic molecular alterations underlying the pathogenesis of this neoplasm. The hallmark of the diagnosis is loss of *SMARCA4* (*BRG1*) expression on immunohistochemical staining. *SMARCA4* deficiency is found in most cases. However, sequencing of *SMARCA4* alteration is not necessary for the diagnosis, as the truncated protein can occasionally be partially recognized by the antibody, which leads to unstable binding and degradation, explaining the attenuated immunoreactivity in certain cases[7]. Additional molecular tests may help confirm the diagnosis of *SMARCA4*-deficient tumors when immunohistochemistry findings cannot be interpreted with certainty [7].

Concurrent loss of the *SMARCA2* expression and expression of one or more stem cell markers, such as sex determining region Y-box 2, SALL4, or CD34, is common. *SMARCA4* deficiency is a passenger somatic alteration in multiple solid tumors manifesting as focal dedifferentiation and a rhabdoid morphology[8]. *SMARCA4*-DUT and non-small cell lung cancer (NSCLC) with *SMARCA4*-deficiency show considerable overlap in their clinicopathological features, such as male preponderance, association with smoking, pattern of metastasis, rapidly fatal outcomes, immunohistology findings, and molecular alterations[1]. Morphologically, *SMARAC4*-DUT is differentiated from *SMARCA4*-deficient NSCLC by the absence of squamous and solid components[9].

However, the incidence of SMARAC4-DUTs is too low to be included in the differential diagnosis of poorly differentiated tumors. To date, approximately 100 cases of SMARCA4-DUTs have been reported in the literature[10]. Further, SMARAC4-DUTs are commonly located in the thorax, from which only small biopsy samples are usually available. The present patient underwent frozen biopsy after endobronchial ultrasound-guided transbronchial lung biopsy and bronchial washing performed twice failed to obtain sufficient amount of tumor cells because of tumor necrosis. Owing to metastasis, other organs, such as the adrenal gland, may be biopsied first[4]. These issues make it difficult to reach a definitive diagnosis.

SMARCA4-DUTs show an undifferentiated morphology with occasional rhabdoid features. Considering histological findings and clinical presentation, such as significant progression at the time of initial diagnosis, it will not be difficult to include *SMARCA4*-DUT in the differential diagnosis using integrase interactor 1 (INI1) staining in the ancillary test.

SMARCA4-DUTs are rapidly fatal and are refractory to conventional therapies. Although responses vary, immunotherapy is promising. The PDL1 expression appears to be of a poor predictive value. Drugs targeting genetic and epigenetic mechanisms of *SMARCA4* antagonism have therapeutic potential[10].

This case demonstrates the typical clinical presentation and morphological features of *SMARCA4*-DUTs: Diffuse sheets of large round to epithelioid poorly cohesive cells with a high nuclear grade and frequent necrosis on frozen sections. Tumor cell nuclei are typically vesicular, monotonous with moderate pleomorphism, and with a markedly increased mitotic activity. These features were also observed in the frozen sections of the tumor in the present case. A clinicopathologic correlation is crucial for patients' care because of the aggressive behavior of the tumor.

Zaishideng® WJCC | https://www.wjgnet.com

CONCLUSION

We report a case of SMARCA4-DUT with characteristic clinical manifestations. This novel subset of tumors should be suspected in patients with rapidly growing mediastinal and pulmonary nodules. The diagnosis can be obtained based on combined clinical features and histopathological features, such as absence of epithelial differentiation and negative SMARCA4 expression.

FOOTNOTES

Author contributions: Kwon HJ and Jang MH contributed to manuscript writing and editing and data collection; Kwon HJ contributed to data analysis; Jang MH contributed to conceptualization and supervision; all authors have read and approved the final manuscript.

Supported by a grant from Yeungnam University, No. 222A580017.

Informed consent statement: The study protocol was approved by the Institutional Review Board of the Yeungnam University Medical Center with a waiver of informed consent.

Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript has been prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: South Korea

ORCID number: Hee Jung Kwon 0000-0002-8800-7690; Min Hye Jang 0000-0002-4270-8897.

S-Editor: Yan IP L-Editor: A P-Editor: Yan JP

REFERENCES

- Perret R, Chalabreysse L, Watson S, Serre I, Garcia S, Forest F, Yvorel V, Pissaloux D, Thomas de Montpreville V, Masliah-Planchon J, Lantuejoul S, Brevet M, Blay JY, Coindre JM, Tirode F, Le Loarer F. SMARCA4-deficient Thoracic Sarcomas: Clinicopathologic Study of 30 Cases With an Emphasis on Their Nosology and Differential Diagnoses. Am J Surg Pathol 2019; 43: 455-465 [PMID: 30451731 DOI: 10.1097/PAS.000000000001188]
- Rekhtman N, Montecalvo J, Chang JC, Alex D, Ptashkin RN, Ai N, Sauter JL, Kezlarian B, Jungbluth A, Desmeules P, 2 Beras A, Bishop JA, Plodkowski AJ, Gounder MM, Schoenfeld AJ, Namakydoust A, Li BT, Rudin CM, Riely GJ, Jones DR, Ladanyi M, Travis WD. SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas. J Thorac Oncol 2020; 15: 231-247 [PMID: 31751681 DOI: 10.1016/j.jtho.2019.10.0231
- 3 Yoshida A, Kobayashi E, Kubo T, Kodaira M, Motoi T, Motoi N, Yonemori K, Ohe Y, Watanabe SI, Kawai A, Kohno T, Kishimoto H, Ichikawa H, Hiraoka N. Clinicopathological and molecular characterization of SMARCA4-deficient thoracic sarcomas with comparison to potentially related entities. Mod Pathol 2017; 30: 797-809 [PMID: 28256572 DOI: 10.1038/modpathol.2017.11]
- 4 Ashour S, Reynolds JP, Mukhopadhyay S, McKenney JK. SMARCA4-Deficient Undifferentiated Tumor Diagnosed on Adrenal Sampling. Am J Clin Pathol 2022; 157: 140-145 [PMID: 34463317 DOI: 10.1093/ajcp/aqab101]
- Yadav R, Sun L, Salyana M, Eric M, Gotlieb V, Wang JC. SMARCA4-Deficient Undifferentiated Tumor of Lung Mass-A Rare Tumor With the Rarer Occurrence of Brain Metastasis: A Case Report and Review of the Literature. J Investig Med High Impact Case Rep 2022; 10: 23247096221074864 [PMID: 35356840 DOI: 10.1177/23247096221074864]
- 6 Wong AK, Shanahan F, Chen Y, Lian L, Ha P, Hendricks K, Ghaffari S, Iliev D, Penn B, Woodland AM, Smith R, Salada G, Carillo A, Laity K, Gupte J, Swedlund B, Tavtigian SV, Teng DH, Lees E. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res 2000; 60: 6171-6177 [PMID: 11085541]
- Kuwamoto S, Matsushita M, Takeda K, Tanaka N, Endo Y, Yamasaki A, Kohashi K, Oda Y, Horie Y. SMARCA4-7 deficient thoracic sarcoma: report of a case and insights into how to reach the diagnosis using limited samples and resources. Hum Pathol 2017; 70: 92-97 [PMID: 28601660 DOI: 10.1016/j.humpath.2017.05.024]
- Chatzopoulos K, Boland JM. Update on genetically defined lung neoplasms: NUT carcinoma and thoracic SMARCA4-



deficient undifferentiated tumors. Virchows Arch 2021; 478: 21-30 [PMID: 33409598 DOI: 10.1007/s00428-020-03011-3]

- 9 Nambirajan A, Singh V, Bhardwaj N, Mittal S, Kumar S, Jain D. SMARCA4/BRG1-Deficient Non-Small Cell Lung Carcinomas: A Case Series and Review of the Literature. Arch Pathol Lab Med 2021; 145: 90-98 [PMID: 33367658 DOI: 10.5858/arpa.2019-0633-OA]
- 10 Nambirajan A, Jain D. Recent updates in thoracic SMARCA4-deficient undifferentiated tumor. Semin Diagn Pathol 2021; **38**: 83-89 [PMID: 34147303 DOI: 10.1053/j.semdp.2021.06.001]





Published by Baishideng Publishing Group Inc 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA Telephone: +1-925-3991568 E-mail: bpgoffice@wjgnet.com Help Desk: https://www.f6publishing.com/helpdesk https://www.wjgnet.com

